

**MINUTES OF THE 2025 ORDINARY GENERAL ASSEMBLY MEETING OF
EİS ECZACIBAŞI İLAÇ, SİNAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET ANONİM ŞİRKETİ
HELD ON 30 APRIL 2026**

The Ordinary General Assembly Meeting of EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret Anonim Şirketi (the "Company") regarding the Company's activities for the year 2025 was held on Thursday, 30 April 2026 at 09:00 a.m. at Wyndham Grand İstanbul Levent Hotel Hezarfen Salonu located at Esentepe, Büyükdere Cd. No:177-183, 34394 Şişli/İstanbul, under the supervision of the Ministry Representative, Ms. Seda Çaycı Akkale, appointed by the T.C. İstanbul Valiliği, İstanbul Ticaret İl Müdürlüğü with its letter dated 28.04.2026 and numbered E-90726394-431.03-00121603317.

The invitation to the meeting was made within the legal period by being announced at least three weeks prior to the date of the Ordinary General Assembly meeting, excluding the announcement and meeting dates, in the manner stipulated by the relevant regulations and the Articles of Association and including the agenda, in the Turkish Trade Registry Gazette dated 3 April 2026 and numbered 11556, on the Public Disclosure Platform (KAP), in the investor relations section of the websites www.eis.com.tr and www.eczacibasi.com.tr, on the Electronic General Assembly System (e-GKS) of the Central Registry Agency (CRA), and on the e-Company Information Portal.

Upon examination of the list of attendees, it was determined that, out of the Company's total issued capital of TRY 685,260,000 corresponding to 68,526,000,000 shares each having a nominal value of 1 Kuruş, 207,042,452.30 shares were represented in person, 55,576,011,381.20 shares by proxy, and 1,034,269,200.00 shares by representatives of depositors, amounting in total to 56,817,323,033.50 shares corresponding to a capital of TRY 568,173,230.335 represented at the meeting; thus, the minimum meeting quorum stipulated by the Turkish Commercial Code and the Articles of Association was met, it was also determined that Board Members Mr. Ferit Bülent Eczacıbaşı, Mr. Emin Fadilloğlu, Ms. İpek Güleç, Mr. İhsan Rifat Öktem, Mr. Erol Ulukutlu, and Ms. Nazlı Aldemir Engin, authorized to represent the independent audit firm DRT Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik Anonim Şirketi were present at the meeting.

Pursuant to the fifth and sixth paragraphs of Article 1527 of the Turkish Commercial Code, it was determined that the Company had fulfilled the preparations for the electronic general assembly meeting in compliance with the legal regulations. Ms. Zübeyde Dindar was appointed to operate the Electronic General Assembly System, and the meeting was simultaneously opened in physical and electronic environments by the Chairman of the Board of Directors, Mr. Ferit Bülent Eczacıbaşı, and the discussion of the agenda items commenced.

As a result of the deliberations held in accordance with the agenda items, the following resolutions were adopted.

1. It was resolved by majority vote, with 56,817,322,933.50 affirmative votes against 100 dissenting votes, to elect Ms. Nil Akman Yurttaş as the Chairperson of the Meeting, and upon the necessity and proposal deemed appropriate by the Chairperson of the Meeting, to appoint Ms. Beyza Banu Can as Minutes Clerk and Ms. Betül Aktekin Aytar as Vote Collection Officer, and to authorize the Meeting Presidency to sign the general assembly meeting minutes.
2. The Chairperson of the Meeting informed the General Assembly that the Company's 2025 Annual Report had been made available for the information and review of the shareholders at the Company Headquarters, in the investor relations section of the websites www.eis.com.tr and www.eczacibasi.com.tr, on the Public Disclosure Platform, on the Electronic General Assembly System of Central Registry Agency, and in the printed 2025 annual report booklets at least 3 (three) weeks before the Ordinary General Assembly meeting within the legal period, and submitted the proposal that the annual report is deemed to have been read to the General Assembly for approval.

It was resolved by majority vote, with 56,812,372,633.50 affirmative votes against 4,950,400.00 dissenting votes, that the Board of Directors' Annual Report for 2025 be deemed as read.

The Company's General Manager, Mr. Emin Fadilloğlu, made a presentation to the General Assembly regarding the Company's activities for 2025 within the framework of the information contained in the 2025 Annual Report.

The Annual Report was opened for discussion.

In summary, the opinions and questions submitted electronically by Mr. Mehmet Selim Tunçbilek alleging that the sale of Company shares carried out by Eczacıbaşı Holding A.Ş. caused a decrease in the share price, that the purchasing institutions sold the shares at prices lower than their acquisition prices, and that the transaction was contrary to the legislation, were read out.

In summary, the opinions and questions submitted electronically by Mr. Ali Bahçuvan were read out, stating that the sale of Company shares by Eczacıbaşı Holding A.Ş. caused a loss in the share value and questioning why the controlling shareholder conducted the sale at a price close to book value.

Mr. Çetin Ganioglu, who attended the meeting physically, took the floor and stated in summary that there was no profitability in healthcare activities, that the main income was expected from real estate, that the Cendere project had not been able to commence for a long time, that there had been no disclosure regarding the subsidiary Vitra Karo, that the fair value of Eczacıbaşı Holding A.Ş. included in the Company's balance sheet had been determined at a low level considering the expected income from the Kartal project, that their expectation as investors was capital appreciation rather than dividends, and that the purchasers of the Company shares sold by Eczacıbaşı Holding A.Ş. had sold the shares at lower prices, expressing criticisms, opinions, and questions to the effect that this transaction had a market-disruptive nature.

Mr. Ferit Erin, speaking on behalf of the Company, stated in summary that the sale of Company shares by Eczacıbaşı Holding A.Ş. was a transaction carried out to strengthen the liquid position of Eczacıbaşı Holding within the framework of the prevailing macroeconomic conditions; that although the Company's share price had been TRY 42 in the same period of the previous year, it was TRY 85 as of the previous day despite the recent negative performance; and that the daily trading volume had also increased and interest from foreign institutional investors, who had not previously shown interest in the Company, had also increased. He further stated that the trading volume of the shares, the amount of the sale made, and macroeconomic and geopolitical conditions simultaneously affected the discount applied in the transaction. Mr. Ferit Erin stated that Ayazağa was still at the project study and preliminary project stage, that procedures within local administrations could sometimes be prolonged, and that maximizing revenue was the primary priority. He stated that the necessary disclosures had been made regarding the Kartal project and that the assumptions expressed by the investors who spoke might not be valid. He stated that the Company's investment properties were valued by a licensed institution and that the valuation made by İŞGYO for Kanyon AVM was also similar. He stated that information regarding Vitra Karo could be found in the notes to the financial statements. Regarding the share sale, he stated that there was no possibility of controlling the actions of the purchasers.

Mr. İhsan Fors, who attended the meeting physically, stated in summary that he could not fully understand the discount applied in the sale and that the sale could also have been made to small investors. Company representative Mr. Ferit Erin, who took the floor, stated that this would not be possible under the legislation.

Mr. Ayhan Güler, who attended the meeting physically, stated in summary, regarding the sale of Company shares by Eczacıbaşı Holding A.Ş., that the purchasers had sold at lower prices, that the funds obtained were very low, and that they could not understand why this sale had been made.

The Chairperson of the Meeting submitted the Company's 2025 Annual Report for the approval of the General Assembly. It was resolved by majority vote, with 2,260,686,200.00 affirmative votes against 54,556,636,833.50 dissenting votes, to approve the Board of Directors' Annual Report for 2025.

3. The Chairperson of the Meeting informed that the Independent Audit Report prepared by DRT Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik A.Ş. for the accounting period 01.01.2025-31.12.2025 had been made available for shareholders' review at the Company Headquarters, in the investor relations section of the websites www.eis.com.tr and www.eczacibasi.com.tr, on the Public Disclosure Platform, and on the Electronic General Assembly System of Merkezi Kayıt Kuruluşu three weeks prior to the General Assembly meeting within the legal period.

The Summary of the Independent Audit Report for 2025 was read by Ms. Nazlı Aldemir Engin, who was present at the meeting on behalf of the Independent Audit Firm, and information was provided to the General Assembly regarding the audit activities and results.

4. The Chairperson of the Meeting stated that the Company's audited Consolidated Financial Statements for the accounting period 01.01.2025-31.12.2025, prepared in accordance with the Capital Markets Board's Communiqué No. II-14.1 on "Principles of Financial Reporting in Capital Markets," had been made available for shareholders' review at least three weeks prior to the date of the Ordinary General Assembly meeting, within the legal period, at the Company Headquarters, in the investor relations section of the websites www.eis.com.tr and www.eczacibasi.com.tr, on the Public Disclosure Platform, on the e-GKS, and in the printed 2025 annual report booklets.

The summary of the balance sheet and income statement for the 2025 accounting period was read and opened for discussion, and no one took the floor. As a result of the voting conducted, it was resolved by majority vote, with 56,718,209,333.50 affirmative votes against 99,113,700.00 dissenting votes, to approve the Consolidated Financial Statements for the 2025 accounting period.

5. The Chairperson of the Meeting informed that the 2024 Sustainability Report compliant with the Türkiye Sustainability Reporting Standards ("TSRS"), for which the mandatory sustainability assurance audit had been completed by RSM Turkey Uluslararası Bağımsız Denetim Anonim Şirketi, had been made available for shareholders' review at the Company Headquarters, in the investor relations section of the websites www.eis.com.tr and www.eczacibasi.com.tr, and on the Public Disclosure Platform, three weeks prior to the General Assembly Meeting within the legal period, and submitted to the approval of the General Assembly the proposal that the 2024 TSRS-Compliant Sustainability Report be deemed as read.

It was resolved by majority vote, with 54,647,684,033.50 affirmative votes against 2,169,639,000.00 dissenting votes, that the 2024 TSRS-Compliant Sustainability Report be deemed as read.

The 2024 TSRS-Compliant Sustainability Report was opened for discussion, and no one took the floor.

The Chairperson of the Meeting submitted the Company's 2024 TSRS-Compliant Sustainability Report for the approval of the General Assembly. It was resolved by majority vote, with 54,647,684,033.50 affirmative votes against 2,169,639,000.00 dissenting votes, to approve the 2024 TSRS-Compliant Sustainability Report.

6. The Chairperson of the Meeting submitted the individual release of the Members of the Board of Directors from liability in respect of the accounts and activities of the year 2025 to the approval of the General Assembly. The Members of the Board of Directors were individually released by majority vote, with 54,637,242,833.50 affirmative votes against 2,180,080,200.00 dissenting votes.
7. The proposal of the Board of Directors regarding the distribution of the Company's profit for the fiscal year 2025, taking into consideration that:

- i. According to the consolidated financial statements prepared on the basis of the Turkish Financial Reporting Standards ("TFRS") in compliance with the Capital Markets Board's Communiqué No. II-14.1 on "Principles of Financial Reporting in Capital Markets" and audited independently, the consolidated net distributable profit for the period attributable to the parent company was TRY 2,088,766,000 and the consolidated net distributable profit for the period including donations was TRY 2,088,767,300,

- ii. According to the statutory financial statements prepared pursuant to the provisions of the Tax Procedure Law ("TPL"), the net profit for the period was TRY 2,534,762,542, and the distributable dividend base reached TRY 2,534,428,027 after deducting prior years' commercial losses amounting to TRY 334,515 from this amount; furthermore, although there were prior years' losses arising from inflation adjustment practices amounting to TRY 13,986,775,693 according to the statutory financial statements prepared under VUK, there were Inflation Adjustment Differences related to Equity Accounts sufficient to cover the total amount of TRY 13,986,775,693, and within this scope, according to the financial statements prepared pursuant to VUK records, there existed a net distributable profit of TRY 2,534,428,027,

- iii. Pursuant to paragraph 1 of Article 519 of the Turkish Commercial Code, the 5% general legal reserve required to be set aside would not be allocated for the year 2025 since the amount in the statutory records had reached the limit of 20% of the issued capital,

and regarding the distribution of our Company's profit for the fiscal year 2025, in accordance with the Capital Markets Legislation, the provisions of the Articles of Association, and the Company's Dividend Distribution Policy:

1. The distribution of a total cash dividend amounting to TRY 1,200,000,000 corresponding to 175% of the Company's issued capital,
2. The allocation of the legal reserve required to be set aside pursuant to subparagraph (c) of paragraph 2 of Article 519 of the Turkish Commercial Code,
3. According to the financial statements prepared pursuant to TFRS provisions, the payment of a total cash dividend of TRY 1,200,000,000 to shareholders from the net distributable profit for the period and the transfer of the remaining balance to retained earnings,
4. According to the statutory records prepared pursuant to TPL provisions, the offsetting of prior years' commercial losses amounting to TRY 334,515 against the current year profit, and in addition, in accordance with tax regulations, not offsetting items arising from inflation adjustment within equity, and meeting the entirety of the total cash payments amounting to TRY 1,200,000,000 from the current year profit, while transferring the remaining TRY 336,571,501 to the extraordinary reserves account,
5. The payment of a gross cash dividend of 175% per share with a nominal value of TRY 1, and payment of dividends to our full taxpayer real person shareholders and limited taxpayer real and legal person shareholders at the net amount calculated after deduction of withholding tax rates stipulated under tax legislation,
6. The commencement of dividend distribution on 6 May 2026,

was read out and opened for discussion. Mr. Çetin Ganioğlu expressed his opinion that they expected capital appreciation rather than dividends.

As a result of the voting conducted, the profit distribution proposal of the Board of Directors and, within this framework, the attached dividend distribution table for 2025, were approved by majority vote, with 56,723,947,833.50 affirmative votes against 93,375,200.00 dissenting votes.

8. Pursuant to Article 4.6.2 of the Capital Markets Board's Communiqué No. II-17.1 on "Corporate Governance," shareholders were informed that the remuneration principles for the Members of the Board of Directors and senior executives had been put into writing by the Company as the "Remuneration Policy," and had been made available for shareholders' information three weeks prior to the General Assembly Meeting within the legal period in the investor relations section of the websites www.eis.com.tr and www.eczacibasi.com.tr, and within the Information Document on the Public Disclosure Platform and the Electronic General Assembly System of Central Registry Agency. Shareholders were also informed that information regarding the benefits provided to the members of the board of directors and senior executives, calculated according to the purchasing power of the Turkish Lira as of 31.12.2025, had been disclosed in Note 9 to the Consolidated Financial Statements dated 31 December 2025.
9. The election of the Members of the Board of Directors was proceeded with. The Chairperson of the Meeting read out the list of candidates for membership of the Board of Directors and stated that the Company had been informed by the Capital Markets Board's letter dated 26.01.2026 that it had been resolved not to express any adverse opinion regarding Mr. İhsan Rifat Öktem and Mr. Erol Ulukutlu, who had been designated as candidates for Independent Board Membership. The Chairperson also informed that the resumes of the candidates for membership of the Board of Directors had been publicly disclosed three weeks prior to the General Assembly Meeting within the Information Document on the Public Disclosure Platform and the Electronic General Assembly System, and had been made available for shareholders' review at the Company Headquarters and in the investor relations section of the websites www.eis.com.tr and www.eczacibasi.com.tr. In accordance with Article 10 of the Company's Articles of Association, for a term of office of 1 (one) year:

- **Mr. Ferit Bülent ECZACIBAŞI**, who declared his candidacy for membership of the Board of Directors through the letter of consent bearing journal number 93863 certified by Beyoğlu 48th Notary Office on 20 April 2026,
- **Mr. Rahmi Faruk ECZACIBAŞI**, who declared his candidacy for membership of the Board of Directors through the letter of consent bearing journal number 93862 certified by Beyoğlu 48th

Notary Office on 20 April 2026,
• **Mr. Emin FADILLIOĞLU**, who declared his candidacy for membership of the Board of Directors through the letter of consent bearing journal number 93864 certified by Beyoğlu 48th Notary Office on 20 April 2026,
• **Ms. İpek GÜLEÇ**, who declared her candidacy for membership of the Board of Directors through the letter of consent bearing journal number 93865 certified by Beyoğlu 48th Notary Office on 20 April 2026,
• **Mr. İhsan Rifat ÖKTEM**, who declared his candidacy for Independent Board Membership through the letter of consent bearing journal number 93859 certified by Beyoğlu 48th Notary Office on 20 April 2026,
• **Mr. Erol ULUKUTLU**, who declared his candidacy for Independent Board Membership through the letter of consent bearing journal number 93860 certified by Beyoğlu 48th Notary Office on 20 April 2026,

were elected as Members of the Board of Directors; it was also resolved by majority vote, with 55,975,627,033.50 affirmative votes against 841,696,000.00 dissenting votes, that no attendance fee be paid to the members other than the independent members in connection with these duties, and that a gross monthly attendance fee (remuneration) of TRY 95,000 be paid to the Independent Members of the Board of Directors.

10. Within the framework of Article 399 of the Turkish Commercial Code and the regulations of the Capital Markets Board, and upon obtaining the opinion of the Audit Committee at the meeting of the Board of Directors dated 27 March 2026, it was resolved by majority vote, with 54,656,250,433.50 affirmative votes against 2,161,072,600.00 dissenting votes, to appoint the Independent Audit Firm DRT Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik A.Ş., registered with the İstanbul Ticaret Sicili Müdürlüğü under registry number 304099 and Mersis number 0291001097600016, as proposed for the auditing of the Company's financial reports for the 2026 fiscal year and for carrying out the other activities within the scope of the relevant regulations, and to execute the service agreement.
11. Within the framework of the Board Resolution of the Public Oversight, Accounting and Auditing Standards Authority ("KGK") regarding the Mandatory Assurance Audits for Sustainability Reports, published in the Official Gazette dated 05 September 2024 and numbered 32653, it was resolved by majority vote, with 54,656,250,433.50 affirmative votes against 2,161,072,600.00 dissenting votes, to appoint RSM Turkey Uluslararası Bağımsız Denetim Anonim Şirketi, registered with the İstanbul Ticaret Sicili Müdürlüğü under registry number 640766 and Mersis number 0645033418600011, as proposed by the Board of Directors to conduct the assurance audits for the 2026 sustainability report and other activities related to the relevant legislation, and to execute the service agreement.
12. Pursuant to Article 6 of the Capital Markets Board's Communiqué No. II-19.1 on "Dividend Distribution," the General Assembly was informed that a donation of TRY 1,300 had been made to Turkish Education Foundation in 2025 (total TRY 1,300 according to the purchasing power of the Turkish Lira as of 31.12.2025), and it was proposed that the upper limit for donations to be made in 2026 be determined as TRY 30,000,000.

It was resolved by majority vote, with 55,843,053,733.50 affirmative votes against 974,269,300.00 dissenting votes, to determine the upper limit for donations to be made in 2026 as TRY 30,000,000.
13. Pursuant to paragraph 4 of Article 12 of the Capital Markets Board's Corporate Governance Communiqué No. II-17.1, the General Assembly was informed that information regarding the guarantees, pledges, mortgages, and sureties provided by the Company and its subsidiaries in favor of third parties for the purpose of conducting ordinary commercial activities, as well as the income or benefits obtained therefrom, had been included in Note 18 to the Consolidated Financial Statements dated 31 December 2025, and that, as stated in the relevant note, there were no guarantees, pledges, mortgages, or sureties provided within this scope.
14. Pursuant to Corporate Governance Principle No. 1.3.6 annexed to the Capital Markets Board's Corporate Governance Communiqué No. II-17.1, shareholders were informed that, in 2025, there had been no transactions involving shareholders holding management control, Members of the Board of Directors, executives with administrative responsibility, or their spouses and blood or affinity relatives up to the second degree, consisting of significant transactions that could create a conflict of interest with the Company or its subsidiaries and/or transactions falling within the business subject matter of the Company or its subsidiaries carried out on their own behalf or on behalf of others, or

participation in another company engaged in the same type of commercial business as a partner with unlimited liability.

15. It was resolved by majority vote, with 54,656,250,433.50 affirmative votes against 2,161,072,600.00 dissenting votes, to grant permission to the Members of the Board of Directors for the year 2026 to perform the activities specified under Articles 395 and 396 of the Turkish Commercial Code.

16. Under the wishes and requests item of the agenda, the shareholders were heard.

In summary, the opinions and questions submitted electronically by Mr. Ali Bahçuvan regarding moving the General Assembly meeting time to 11:00 a.m., the company management's projections regarding macroeconomic indicators, and whether the risks had been hedged, were read out.

Mr. Faruk Memiş, who attended the meeting physically, stated in summary that the increase in the share price stemmed from real estate projects, that Eczacıbaşı Holding A.Ş. had made many sales, both small and large, within the last two years, and expressed his opinions and questions as to whether there were plans for further sales.

Mr. Çetin Ganioglu stated in summary that there was a contraction on the pharmaceutical side, that they did not expect significant growth or profitability, questioned why the Cendere project had not commenced, stated that the Company's book value should be much higher, and expressed his opinion and questions that it would be appropriate to invite analysts to the investor meetings held.

Mr. Hüseyin Samim Emanet expressed in summary his opinions and questions regarding the delivery date of the Kartal project and the risks in the healthcare sector.

Mr. Sadık Akay expressed in summary his opinions and questions that the fact that the purchasers of the Company shares sold by Eczacıbaşı Holding A.Ş. were selling at prices lower than their purchase prices gave rise to suspicion.

The Company's General Manager, Mr. Emin Fadilloğlu, stated in summary that, from the perspective of the pharmaceutical industry, predictability in inflation and pricing created risks, that risks did exist, but that when looking at the dynamics, opportunities outweighed the risks.

Mr. Ferit Erin, speaking on behalf of the Company, stated in summary that the entity conducting the share sale was Eczacıbaşı Holding A.Ş., and therefore no funds would flow to the Company from this transaction; that there was no possibility of using this transaction as the source for the Company's dividend distribution; and that Eczacıbaşı Holding, not being a publicly traded company, had carried out this sale in order to strengthen its balance sheet and provide flexibility. He stated that Eczacıbaşı Holding actively managed its own subsidiary portfolio and that, when profitability reached high levels, an approach could be adopted in line with sectoral dynamics. He further stated that, in the Sanipak sale, it had been assessed that the asset had reached its value; that the Ayazağa project was continuing; that any income projection at this stage could be misleading; that investor meetings would continue; that meetings had been held with brokerage firms and portfolio management companies; that the proceeds from the Kartal sale would not be reflected in the Company's income statement; that there was no possibility of intervening in the decisions of the purchasers following the share sale; that necessary measures had been taken regarding currency risk within the framework of the financing strategy; and that, at present, there was no new asset sale on the agenda.

Mr. Bülent Eczacıbaşı, who took the floor, thanked the investors and stated in summary that the message regarding investors' dissatisfaction with the sale of Company shares by Eczacıbaşı Holding A.Ş. had been received, that they managed their companies with long-term evaluations rather than short-term considerations, and that it was important for the Company to preserve its value in the long term through good management.

As there were no further matters to be discussed on the agenda, the Chairperson of the Meeting thanked the General Assembly and closed the meeting.

These minutes were prepared and signed at the meeting venue following the meeting.

30 April 2026

Annex-1: Profit Distribution Table

MINISTRY REPRESENTATIVE
SEDA ÇAYCI AKKALE

CHAIRPERSON OF THE MEETING
NİL AKMAN YURTTAŞ

MINUTES CLERK
BEYZA BANU CAN

VOTE COLLECTION OFFICER
BETÜL AKTEKİN AYTAZ

EİS ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş.
DIVIDEND DISTRIBUTION TABLE FOR 2025 (TL)

1.	Paid-in/Issued Capital		685.260.000
2.	Total Legal Reserves (According to Legal Records)		137.052.000
Information on privileges in dividend distribution, if any, in the Articles of Association:			There are no preferred shares.
		Based on CMB Regulations	Based on Legal Records
3.	Current Period Profit	2.982.057.000	2.727.595.892
4.	Taxes Payable (-)	894.237.000	192.833.350
5.	Net Current Period Profit (=)	2.088.766.000	2.534.762.542
6.	Losses in Previous Years (-)	0	334.515
7.	Primary Legal Reserve (-)	0	0
8.	NET DISTRIBUTABLE CURRENT PERIOD PROFIT (=)	2.088.766.000	2.534.428.027
9.	Donations Made During The Year (+)	1.300	0
10.	Donation-Added Net Distributable Current Period Profit on which First Dividend is Calculated	2.088.767.300	2.534.428.027
11.	First Dividend to Shareholders		
	- Cash	208.876.730	34.263.000
	- Stock	0	0
	- Total	208.876.730	34.263.000
12.	Dividend Distributed to Owners of Privileged Shares	0	0
13.	Other Dividend Distributed	0	
	- To the Members of the Board of Directors	0	0
	- To the Employees	0	0
	- To Non-shareholders	0	0
14.	Dividend to Owners of Redeemed Shares	0	0
15.	Second Dividend to Shareholders	991.123.270	1.165.737.000
16.	Secondary Legal Reserves	116.573.700	116.573.700
17.	Statutory Reserves	0	0
18.	Special Reserves	0	0
19.	EXTRAORDINARY RESERVES	772.192.300	336.571.501
20.	Other Distributable Resources	0	0
	- Extraordinary Reserves	0	0
		0	0

INFORMATION ON DIVIDEND PER SHARE

	SHARE GROUP	TOTAL DIVIDEND AMOUNT		TOTAL DIVIDEND AMOUNT / NET DISTRIBUTABLE CURRENT PERIOD PROFIT	DIVIDEND TO BE PAID FOR SHARE WITH PAR VALUE OF 1 TL		
		CASH	(TL)	STOCK (TL)	RATIO (%)	NET (TL)	NET (%)
NET	-	1.020.000.000		0	48,83	1,4885	149

(*) The net values of dividends per share have been calculated with the assumption that the dividends are distributed to the full taxpayer real person shareholders and there is no earning that is subject to any exemption in the distribution, thus accepting the withholding rate at 15% in accordance with the Presidential Decision dated 21/12/2024 and numbered 2024/9286.

(**) The net profit of the parent company is considered as the net distributable current period profit.

(***) Following the sale of our 50% shareholding in Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş., 50% of the share sale gain, amounting to TRY 881,282,826, has been transferred to a special fund account in order to benefit from the exception specified in subparagraph (e) of paragraph (1) of Article 5 of the Corporation Tax Law No. 5520. This amount is included in the "Statutory Period Profit" under the "According to Legal Records" column in the table; however, as the relevant exempt income has been transferred to the fund account, it is not taken into account in the subsequent calculations made in accordance with the legal records (TPL).